The global eosinophilic granulomatosis with polyangiitis treatment market is on the cusp of significant expansion, according to recent market analysis. The market, which was valued at USD 173.8 million in 2023, is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.2%, reaching an impressive USD 288.5 million by 2033.
Several key factors are driving this upward trajectory. Advancements in healthcare technology have played a pivotal role, enabling more effective and targeted treatment options for patients suffering from EGPA, also known as Churg Strauss syndrome. This rare condition, characterized by inflammation of blood vessels, leads to restricted blood flow to various organs and tissues.
Get Sample Report Visit to learn about recent in the Eosinophilic Granulomatosis with Polyangiitis Treatment Market observed by FMI
The increasing demand for EGPA treatment is fueled by heightened patient awareness and the availability of effective therapeutics. Developed economies, buoyed by government initiatives and improvements in healthcare infrastructure, and are expected to witness substantial market growth.
Moreover, the market benefits from the presence of numerous manufacturers with robust drug pipelines and substantial investments in research and innovation, further accelerating its promising trajectory.
“EGPA is a condition that demands effective treatment solutions, and the market is responding with innovative therapies and heightened accessibility,” stated FMI. “As we navigate demographic shifts and technological advancements, the market’s growth is poised to address the evolving needs of patients worldwide.”
Key Takeaways from the Market Study:
- As of 2023, the eosinophilic granulomatosis with polyangiitis treatment market was valued at USD 173.8 Million
- From 2023 to 2033, the eosinophilic granulomatosis with polyangiitis treatment industry is poised to grow at 5.2% CAGR
- By 2033, the eosinophilic granulomatosis with polyangiitis treatment market is slated to reach a valuation of USD 288.5 Million
- Based on the distribution channel, hospital pharmacy segment accounts for market share of 35.7% during the forecast period.
- China is poised to yield a CAGR of 4.8% with respect eosinophilic granulomatosis with polyangiitis treatment in 2033.
Competitive Landscape:
- Genentech Inc
- F. Hoffmann-La Roche AG
- Cephalon Inc.
- Teva Pharmaceutical Industries Ltd.
- Amgen Inc.
- Sanofi S.A.
- Koninklijke DSM N.V
- AstraZeneca
- Novartis International AG
- GlaxoSmithKline LLC
- Baxter Healthcare Corporation
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industries.
- In April 2021 – Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application for Xolair®(omalizumab) prefilled syringe for self-injection across all approved U.S. indications. Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
- In December 2020– Amgen announced that the S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis), and Microscopic Polyangiitis (MPA).
Instant Report Access – Empower Your Strategy with Key Insights
Key Segments Covered in Eosinophilic Granulomatosis with Polyangiitis Treatment Industry Survey:
Eosinophilic Granulomatosis with Polyangiitis Treatment Market by Drug Class:
- Steroids
- Immunosuppressant
- Biologics
- Immune Globulins
Eosinophilic Granulomatosis with Polyangiitis Treatment Market by Route of Administration:
- Oral
- Intravenous
- Intramuscular
Eosinophilic Granulomatosis with Polyangiitis Treatment Market by Distribution Channel:
- Hospital Pharmacies
- Drug stores
- Retail Pharmacies
- Online Pharmacies
Eosinophilic Granulomatosis with Polyangiitis Treatment Market by Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
